fda import alert green list glp-1 semaglutide tirzepatide 2025 SFDA updates guidelines for pharmaceutical variation requirements 🚨Big shifts in the GLP-1

GLP-1 450-750 GLP-1 - 1 2 T2D 450-750 GLP-1 30%-50% 20351500 GLP-1 20%-25% 30%-50% 450-750 GLP-1 2025 danuglipron orforglipron 20 + GLP-1 6 / Kailera15 + GLP-1 + HDM1002 HRS-7535 III orforglipron 1-2 Regor RGT-075 I/II 10%-30% GLP-1 1 GLP-1 BD 120+ GLP-1 III 6 HRS-7535/HRS-9531 NewCo HS-10535 2025 SYH2086 Madrigal2026 20 15+ HDM1002 III IBI3032 I TQF3250 IND BD Regor RGT-075 IIb 202512 2 BD + GLP-1 2030 61%34%2024-2025 4 - - GLP-1 orforglipron 188.8 137.65 / 2 GLP-1 1 orforglipron orforglipronIII 36mg 72 T2D 9.1%-11.5% 10.3% 25mgIII 64 11% 7% HRS-7535180mg 36 BMI 32.5 37-39 8.0%Regor RGT-075125mg IIa 12 5.0% 2 / + MindRank MDR-001240mg 43.8% HRS-7535180mg 43.8% orforglipron10.3% Regor RGT-075 danuglipronScaffold B Scaffold B HDM1002 800 2026 I 3 - + orforglipron OSAIII / T2D HRS-7535 + HFpEFII Scaffold B GLP-1 Scaffold Aorforglipron Scaffold Bdanuglipron Scaffold B HDM1002 Scaffold A 10%-30% orforglipron danuglipron - Kailera - FTO GLP-1 III 17.5% 20.9% CDMO GLP-1 1 600276.SS/1276.HK NewCo HRS-7535/HRS-9531 6 B 19.9% + royalties III 2026 180mg 8.0% 3692.HKHS-10535 2025 HS-10501 II 2026 II 1093.HKSYH2086 Madrigal2026 + MASH Madrigal 2 BD000963.SZHDM1002 GLP-1 III 2026 Scaffold B GLP-1/GIP DR10624MASH II 1801.HKIBI3032 I preclinical 5-10 2026 I BD 1177.HKTQF3250orforglipron IND2026 I / T2D 3CDMO GLP-1 CDMO 2269.HK CDMO 23 GLP-1 24%2025 TIDES / 142% GLP-1 GLP-1 30%-40% III danuglipron 2025 12 Regor RGT-075 IIb 2026 / III Scaffold A 2027 GLP-1 50%+ GLP-1 GLP-1 450-750 III / I CDMO 2025 12 Regor IIb 2026 / III ()

L- L-

Intranasal corticosteroid sprays and antihistamine eye drops are useful adjuncts for allergy management post-surgery, as they are unaffected by changes in gastrointestinal absorption

Science and Engineering of Polyphenols: Fundamentals and Industrial Scale Applications